



ACS Publications
Most Trusted. Most Cited. Most Read.

SUCCESS STORY:

Barrier-free access to ACS content is a critical component of biotech firm's success.

“The ACS All Access Subscription has been of tremendous advantage compared to alternative options that we explored”

Dr. Peter Toogood
Senior Vice President of Chemistry and Chemical Biology, Lycera

“The ACS All Access Subscription provides us with a basis for enhanced creativity.”

ACS ALL ACCESS AND LYCERA

Chemistry and related sciences continue to grow more complex and specialized. With that increased focus comes additional demand from the scientific community for high-quality technology and publishing venues. ACS Publications provides rapid acceptance of essential, cutting-edge research across a broad spectrum of dedicated titles. In addition to award-winning new products, ACS Publications' established portfolio continues to exceed expectations and remains the world's most trusted, most cited, and most read collection of journals in the chemical and related sciences.

In addition to being one of the world's most respected publishing outlets for primary research, ACS Publications makes up a critical component of the problem solving effort that goes into developing commercializable technology for today's high tech economy. Whether an organization is seeking to develop a new therapy for disease or is looking to invent a scratch-proof cell phone screen, the path to discovery often runs through primary research like that in peer-reviewed journals and e-books. Unlike the recent past, current solutions are most often multidisciplinary in nature. One solution may find its roots span from foundational science, such as theoretical chemistry, to applied sciences like sensors or materials. Organizations with the most successful R&D efforts have learned that in order to compete, they can no longer limit their researchers' access to information into subject-level compartments.

ACS is evolving right along with companies, providing new and affordable ways to ensure researchers have access to everything they need to remain current, solve problems, and influence serendipitous discovery. The ACS All Access Subscription provides access to all ACS content for an entire corporation at a price that competes with other publishers' single journal subscriptions. Companies that increase their access to the entire ACS Publications portfolio find that, on average, their previous plan supplied at most 47% of the ACS content they needed. One particularly high-profile company that has reaped the benefits of the ACS All Access Subscription is Lycera.



*Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting
May 30, 2018*

*Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Model
May 16, 2018*

Companies find their previous plan supplied at most 47% of the ACS content they needed.

ACS CUSTOMER PROFILE: LYCERA CORPORATION

Founded in 2006, Lycera is a private biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. Lycera's mission is to develop and advance new classes of therapeutics that can selectively suppress or activate the immune system, with the potential to transform the treatment and outcomes for patients suffering from serious immune-related diseases. Based on its world-class R&D engine, Lycera is advancing clinical candidates from distinct—yet complementary—areas of research, including immune metabolism, cell signaling, and immune cell differentiation.

Lycera began subscribing to ACS Publications in 2016 and since then, utilization of ACS content has grown by more than 300%.



Lycera Corp.

1350 Highland Drive Suite A
Ann Arbor, MI 48108
734.233.3060
info@lycera.com



Peter L. Toogood, Ph.D.

Senior Vice President of Chemistry and Chemical Biology, Lycera

Dr. Peter L. Toogood, a member of the ACS for 29 years and a regular author in ACS journals, is the winner of the 2016 Heroes of Chemistry Award from ACS, an honor that recognizes scientists whose work has led to the development of successful commercialized products for the benefit of humankind. Dr. Toogood joined Lycera in 2007 as VP of

Chemistry and Chemical Biology. He previously held the titles of senior research associate, associate director, and research fellow at Parke-Davis/Pfizer in Ann Arbor, Michigan. His drug discovery experience encompasses the fields of immunology/inflammation, infectious diseases, and cancer. Dr. Toogood was a co-inventor of the cyclin-dependent kinase-4 inhibitor Palbociclib. Before joining Parke-Davis, Dr. Toogood served on the chemistry faculty of the University of Michigan in Ann Arbor, where he established an NIH and NSF funded research program in natural products total synthesis and chemical biology.

Dr. Toogood received his Ph.D. from Imperial College, London, working with Professor Steven V. Ley, and was a NATO postdoctoral fellow in the laboratory of Professor Jeremy R. Knowles at Harvard University.

He is an author of more than 40 peer-reviewed publications and an inventor on 20 issued patents and pending patent applications. Dr. Toogood is also an adjunct professor at the University of Michigan, College of Pharmacy.

GOOD BUSINESS RESULTS FOLLOW GOOD SCIENCE

Given his impressive record of accomplishment in commercial drug research, it is no surprise that Dr. Toogood has a deep appreciation of the need for unlimited access to high-quality scientific content without barriers. “The ACS All Access Subscription has been of tremendous advantage to us at Lycera compared to alternative options that we explored,” says Toogood. “Working at the interdisciplinary interface that is medicinal chemistry, we require access to journals covering a range of topics including organic chemistry, medicinal chemistry, chemical biology, process chemistry, chemical information, biochemistry, catalysis, and more.”

Toogood describes how his team uses their ACS All Access Subscription for both “directed retrieval of references for the specific technical information provided” as well as “perusal of the most recent journal issues to stay current while ‘dipping in’ to individual articles as interest dictates.” Researchers at Lycera have also chosen ACS to publish their own findings. Toogood states that if budgetary concerns made it necessary to choose only a select set of ACS journals, it would greatly limit the routine research and exploration undertaken. This could have a potential effect on the company’s pipeline, which presently has a large stake in the discovery phase for new targets in immune-oncology.

THE VALUE OF PREMIUM CONTENT

Dr. Toogood goes on to explain that although there are obvious immediate cost savings to limiting researchers’ access, narrower access would have a knock-on effect both in terms of convenience and cost, because additional time may be spent looking for content. Additionally, limiting access to premium journals may result in researchers being forced to rely on less pertinent alternative publications. Dr. Toogood’s position is that “for staying current with the literature, the ability to peruse articles without first having to perform a mental cost/benefit calculation ensures that our chemists can stay up-to-date without worrying about paying a fee for each individual article that looks interesting in a Table of Contents. This allows for the kind of broad reading and awareness that promotes the identification of new connections and unanticipated relationships.”

It’s clear that for distinguished researchers like Dr. Toogood, the convenient and efficient access to premium content provided by ACS is unparalleled. “ACS All Access provides us both a productivity advantage (less time navigating paywalls) and also a basis for enhanced creativity,” he explains. “I commend the ACS for creating such an efficient and cost-effective mechanism that allows companies like Lycera to tap into the full value offered by the whole family of ACS journals.”

Want to see if ACS All Access can benefit your company the way it has Lycera?

We have access options for organizations of all types and sizes. Contact us and we'll be glad to help you choose the option that is the best fit for your needs.

CONTACT US:

acspubsales@acs.org

connect.acspubs.org/GetAccess

USA & CANADA: 888-338-0012

WORLDWIDE: +1-614-447-3674

**Get free access to hot ACS articles and more content like this.
Visit CONNECT.ACSPUBS.ORG/INSIDER to become an ACS Industry Insider.**